Click here to view the July edition of Dates for Your Diary
News
Alderley Park, Cheshire – Infex Therapeutics is pressing ahead with a major development of its pandemic resilience strategy by today announcing an agreement with CRUK Newcastle Drug Discovery Unit. This will in-licence a novel therapy designed to treat SARS-CoV-2 along with future variants and a broad spectrum of coronaviruses.
The program, PAN-X, is an early stage drug that has shown encouraging activity during in-vitro testing.
- Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor
- Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology
AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.
- Enables accurate modelling of the human colon and the mucosal barrier
- Provides new insights to the relationship between human microbiome and effect on human health
- Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ microphysiological systems
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development
Appointment supports international growth within ion channel contract research and drug discovery
Reading Scientific Services Ltd (RSSL) has enhanced its Investigative and Quality Control (QC) capabilities with the installation of a new 600 MHz Bruker AVANCE NEO Nuclear Magnetic Resonance (NMR) spectrometer at its UK laboratories. The investment not only increases the scientific consultancy’s capacity to develop tailored analytical solutions, it also paves the way for further investigations into new NMR applications for the Life Science sectors.
Cambridge, United Kingdom – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).